[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349526-105":59,"doc-detail-349526-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","editorial-toward-prognostic-precision-in-the-management-of-gastroenteropancreatic-neuroendocrine-neoplasms","Editorial - Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms","","Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), spanning well-differentiated neuroendocrine tumors and poorly differentiated high-grade neuroendocrine carcinomas, represent a heterogeneous and rising set of diseases that complicates diagnosis and treatment. This Special Collection synthesizes four perspectives on GEP-NEN management, including clinicopathological prognostic factors, sex-related survival differences, comparative real-world outcomes of long-acting somatostatin analogs, and tumor-burden assessment using somatostatin receptor imaging. The editorial links findings to risk-adapted, personalized care integrating tumor biology with patient characteristics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/editorial-toward-prognostic-precision-in-the-management-of-gastroenteropancreatic-neuroendocrine-neoplasms/349526/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/editorial-toward-prognostic-precision-in-the-management-of-gastroenteropancreatic-neuroendocrine-neoplasms/349526.png","ImageObject",300,407,{"name":92,"@type":93},"PakDamar76","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the editorial focus on in GEP-NEN management?","Question",{"text":112,"@type":113},"It addresses the need to move from asking which treatment is best overall to determining which approach fits a particular patient, using prognostic information.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which four perspectives are brought together in the Special Collection?",{"text":117,"@type":113},"Clinicopathological prognostic factors, sex-related survival differences, real-world comparative use and outcomes of long-acting somatostatin analogs, and tumor burden assessment using somatostatin receptor-based imaging.",{"name":119,"@type":110,"acceptedAnswer":120},"How do the studies support more personalized treatment strategies?",{"text":121,"@type":113},"By showing that combining tumor biology with patient characteristics (such as age and sex) can improve risk estimation and tailor therapy, moving away from one-size-fits-all care.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349526,1790772957,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":19,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":52,"preview_page_count":19,"preview_urls":144},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Editorial: Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms  \nCancer Control Volume 33: 1–4 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)  \n[DOI: 10.1177/10732748261476087](DOI: 10.1177/10732748261476087)  \n[journals.sagepub.com/home/ccx](journals.sagepub.com/home/ccx)  \nAbstract  \nGastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which encompass well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs), are a clinically and pathologically heterogeneous group of diseases with an increasing incidence, presenting significant challenges in diagnosis and treatment. This Special Collection brings together studies examining GEP-NEN management from four distinct perspectives: clinicopathological prognostic factors, sex-related survival differences, comparative real-world use and outcomes of long-acting somatostatin analogs, and tumor burden assessment using somatostatin receptor-based imaging. This editorial connects the studies in the collection, discussing the evolving field toward risk-adapted and personalized management of GEP-NENs, ie., a prognostic approach that integrates tumor biology with patient characteristics.  \nPlain Language Summary  \nNeuroendocrine tumors of the stomach, intestines, and pancreas (known as GEP-NETs) are an uncommon and very mixed group of cancers. They behave in very different ways from one person to the next: some grow slowly and cause few problems for years, while others are high-grade and spread quickly and are harder to treat. Because of this variety, no single treatment works well for everyone, and doctors increasingly ask not just “which treatment is best?” but “which approach is best for this particular patient?” This collection brings together four studies that each tackle this question from a different angle. One study of patients treated with surgery found that older age, a more aggressive tumor type, and more advanced disease were linked to poorer survival. A second, very large study found that women tended to live longer than men, even after accounting for other differences. A third study comparing two long-acting medicines (lanreotide and octreotide) found a possible difference in outcomes between them, but because the groups differed in important ways, this finding needs to be confirmed before it can guide treatment. A fourth study showed that an imaging scan measuring the total amount of active tumor in the body predicts outcomes better than a scan that only measures the single most active spot. Taken together, these studies point in the same direction: better care comes from combining information about the tumor’s biology with details about the patient, such as age and sex, to estimate risk and tailor treatment to each person. Because most of this evidence comes from looking back at past records, larger forward-looking studies are still needed to confirm the findings. The overall message is that “one-size-fits-all” care is giving way to more personalized, risk-based treatment.  \nKeywords  \ngastroenteropancreatic neuroendocrine neoplasms, prognostic factors, risk-adapted management, precision oncology, somatostatin receptor, tumor heterogeneity  \nGastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), which encompass well-differentiated neuroendocrine tumors (NETs) and poorly differentiated, high-grade neuroendocrine carcinomas (NECs) as defined by the 2022 World  \nCorresponding author:  \nMuhammer Ergenç, MD, FEBS, Department of General Surgery, Marmara University School of Medicine, Başıbüyük Campus, Başıbüyük Mah., Maltepe Başıbüyük Yolu Sok, No: 9/2, Maltepe, Istanbul 34854, Turkey.  \n[Emails:](Emails: muhammer.ergenc@marmara.edu.tr)[ muhammer.ergenc@marmara.edu.tr](Emails: muhammer.ergenc@marmara.edu.tr); [muhammerergenc@gmail.com](muhammerergenc@gmail.com)  \nCreative Commons Non Commercial CC BY-NC: Thi","cbCainOIyDuhq0Lp","https://ap.wps.com/l/cbCainOIyDuhq0Lp","pdf",602551,"English","# Abstract\n## Plain Language Summary\n## Keywords\n## Management Perspectives in the Special Collection","[{\"question\":\"What problem does the editorial focus on in GEP-NEN management?\",\"answer\":\"It addresses the need to move from asking which treatment is best overall to determining which approach fits a particular patient, using prognostic information.\"},{\"question\":\"Which four perspectives are brought together in the Special Collection?\",\"answer\":\"Clinicopathological prognostic factors, sex-related survival differences, real-world comparative use and outcomes of long-acting somatostatin analogs, and tumor burden assessment using somatostatin receptor-based imaging.\"},{\"question\":\"How do the studies support more personalized treatment strategies?\",\"answer\":\"By showing that combining tumor biology with patient characteristics (such as age and sex) can improve risk estimation and tailor therapy, moving away from one-size-fits-all care.\"}]","Editorial - Toward Prognostic Precision in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms | PDF",1790084175,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2f0e198b2517d290cc8333b6020acef6.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e0c3f40516e1b351dd30a5b375ea600b.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a55683e82cffd8aa7be27ffd23c63e24.webp",981,1308,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/821ea4eedf4af4b5c90f5cdb69e22bfe.webp",980,1306]